<DOC>
	<DOCNO>NCT00890240</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( process JNJ-31001074 absorbed , distribute , metabolize , eliminate body ) single dose JNJ-31001074 . Up three dose strength test patient 6-11 year old attention deficit hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety Tolerability After Single Dose Administration JNJ-31001074 Children ( 6-11 Years ) With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This open-label ( physician patient know treatment administer ) , multicenter , sequential-group ( one group another ) , single-dose , Phase I study 6-11 year old patient attention deficit hyperactivity disorder ( ADHD ) . Patients first group administer single dose JNJ-31001074 observe test ( blood urine sample collect ) period time . If exhibit adverse side effect data collect within predict safe value , dose increased new group patient . Three dose group plan ( 0.015 , 0.045 0.15 mg/kg ) 18 patient complete study . The study consist screen phase , open-label treatment phase , end-of-study/early withdrawal assessment . During screening , patient require give assent participate ( agreement participate ) study parents/guardians require provide consent . Patients evaluate see meet selection criterion specify protocol . Patients meet selection criterion screen report study center even prior Day 1 confirm continue meet eligibility requirement . If patient still eligible , admit study center require fast ( food beverage ) least 4 hour prior dose . On Day 1 , single dose either 0.015 , 0.045 0.15 mg/kg JNJ-31001074 administer approximately 8 , follow multiple blood sample urine collection . At Investigator 's discretion , patient may discharge Day 3 last blood urine sample take , alternatively , may discharge Day 1 12-hour blood urine sample take . In latter case , patient require return study center Day 2 Day 3 additional blood urine sample . Parent ( ) may remain study center child . Patients first dose group study receive single 0.015 mg/kg dose JNJ-31001074 . The data obtain patient first dose group review prior second dose group ( 0.045 mg/kg ) start . Data obtain patient second dose group review prior third dose group ( 0.15 mg/kg ) start . All patient require return study site end study / early withdrawal assessment . The maximum duration participation patient expect 24 day . Depending body weight dose group participate ( 0.015 mg/kg , 0.045 mg/kg 0.15 mg/kg ) , patient dose combination 0.25 , 1 , 3 , 5 mg tablet JNJ-31001074 administer orally .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Boys girl Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) diagnosis ADHD Height weight within 5th 95th Physical Growth National Center Health Statistics percentiles age sex Clinically stable change management ADHD least 1 week prior screen Clinical Global Impression Severity Illness ( CGIS ) score must 3 less screening Children capable provide assent ( typically 7 year age old ) must sign assent form History current clinically significant medical illness DSMIV diagnosis psychiatric disorder ADHD Have take methylphenidate , amphetamine , stimulant medication within 5 halflives screen atomoxetine within 30 day screen Use prescription nonprescription medication except acetaminophen within 14 day plan dose study drug Positive test drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>JNJ-31001074</keyword>
</DOC>